In October 1998 the neurosciences division of SmithKline Beecham's Central Medical Affairs (CMAT) department distributed a position paper, "Seroxat/Paxil Adolescent Depression: Position piece on the phase III clinical studies."
It stated that study 329 had shown "trends in efficacy in favour of Seroxat/Paxil across all indices of depression .. [but had] failed to demonstrate a statistically significant difference from placebo on the primary efficacy measures."